Solventum Corporation

Solventum Corporation

SOLVยทNYSE

$78.36

+2.5%
HealthcareMedical - Care Facilities

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.

At a Glance

Live Snapshot
Market Cap$13.57B
EPS8.9400
P/E Ratio8.77
Earnings Date08/06/2026
3Y-78.0%
5Y-82.0%
10Y-82.0%
3Y-1206.0%
5Y+1127.0%
10Y+1127.0%
3Y+109.0%
5Y+38.0%
10Y+38.0%
SOLV

Solventum Corporation Cash Conversion Engine

SOLV ยท NYSE
Net Income1.56B
Depreciation & Amortization489.00M
Stock-Based Compensation161.00M
Change in Working Capital-119.00M
Others-1.60B
Capital Expenditures-379.00M
Free Cash Flow-10.00M

Cash Flow Quality Analysis

FCF Conversion Rate

-0.6%

Negative free cash flow despite positive earnings raises concerns about cash generation ability or heavy capital requirements.

CapEx Intensity

102.7%

Very high capital intensity consumes most operating cash flow. Limited flexibility for dividends or debt reduction.

FCF Growth Trend

-101.2%

Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.

Working Capital Impact

-$119.00M

Significant working capital drain. Growth may be consuming cash through inventory buildup or receivables extensionโ€”monitor closely.

Cash Flow Quality Insight

Cash flow concerns: Despite profitability, the company is burning cash. Review working capital management, CapEx levels, and sustainability of current operations.

Solventum Corporation Cash Flow Statement

SOLV โ€ข NYSE

Solventum Corporation Cash Flow StatementDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
OPERATING ACTIVITIES
1.6B
479M
1.3B
1.3B
1.5B
1.1B
489M
555M
561M
578M
597M
599M
-120M
-155M
-142M
-141M
-34M
-54M
161M
112M
39M
37M
38M
35M
-1.6B
34M
-15M
64M
74M
74M
(0.0)
(244M)
(0.0)
(0.0)
(0.0)
(0.0)
-119M
160M
126M
-202M
67M
234M
369M
1.2B
1.9B
1.7B
2.2B
2B
INVESTING ACTIVITIES
-379M
-380M
-290M
-251M
-277M
-271M
-696M
(0.0)
(60M)
(0.0)
(0.0)
(0.0)
0.0
0.0
0.0
0.0
0.0
469M
3.9B
0.0
0.0
-2M
-1M
30M
(2.8B)
-380M
-230M
-253M
-278M
(228M)
FINANCING ACTIVITIES
-3.1B
8B
0.0
0.0
0.0
-445M
13M
-8.2B
-1.6B
-1.5B
-2B
-1.8B
-3.1B
-240M
-1.6B
-1.5B
-2B
-2.2B
CASH FLOW SUMMARY
7M
3M
0.0
4M
3M
-3M
116M
568M
133M
-30M
-33M
40M
762M
194M
61M
91M
124M
84M
878M
762M
194M
61M
91M
124M
-10M
805M
1.6B
1.4B
1.9B
1.8B

SEC Filings

SOLV - Filing history and reports

Filing TypeFiling DatePeriod EndingFiscal YearActions
8-K

8-K 2026

N/A

May 27, 2026
May 21, 2026
2026
8-K

8-K 2026

N/A

May 20, 2026
May 15, 2026
2026
10-Q

10-Q 2026 Q1

Q1

May 05, 2026
March 31, 2026
2026
8-K

8-K 2026

N/A

May 05, 2026
May 05, 2026
2026
DEF 14A

DEF 14A 2025

N/A

March 27, 2026
December 31, 2025
2025
8-K

8-K 2026

N/A

March 24, 2026
March 20, 2026
2026
10-K

10-K 2025 FY

FY

February 27, 2026
December 31, 2025
2025
8-K

8-K 2026

N/A

February 26, 2026
February 26, 2026
2026
8-K

8-K 2025

N/A

December 16, 2025
December 16, 2025
2025
10-Q

10-Q 2025 Q3

Q3

November 06, 2025
September 30, 2025
2025
Showing 1 to 10 of 40 filings